Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2005

View Archived Issues

NB-001 successfully completes phase II study in herpes labialis

CRADA for antiviral testing of Tarvacin

SC-236 attenuates colon tumor activity associated with cigarette smoking

First dual modulator of PGI2 and TXA2 shows promise as an antithrombotic agent

New class of intestinal Pi absorption inhibitor

Japanese Committee for Usage of Unapproved Drugs rules on Chugai drugs

Nonapprovable letter for Namenda for mild Alzheimer's disease

Vernalis completes acquisition of Ionix

Acambis' C. difficile vaccine begins phase I study

Phase III study of MyVax Personalized Immunotherapy cleared to continue

Tapestry to focus on development of TPI-287

U.K. phase I study of Reolysin begins enrollment

Ozarelix begins U.S. phase I/II trial for hormone-dependent prostate cancer

Adacel vaccine now available in U.S.

Novacea and Pierre Fabre partner on oral vinorelbine

Recent patents cover novel treatments for cognitive disorders

Trifunctional bispecific antibodies show promise in the treatment of cancer

Zegerid Chewable Tablets NDA accepted for filing

Blockade of melanocortin-4 receptors increases the potency of morphine

Novel anti-HIV agents reported by Panacos

NDA for indiplon tablets accepted for review

(-)-Gossypol induces apoptosis in cisplatin-resistant head and neck cancer cells

Salagen approved in Japan

Ruboxistaurin reduces vision loss risk in patients with diabetic retinopathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...